Relationship between Lipoprotein(a) and Dyslipidemia in the Elderly over 60 Years
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The relationship between lipoprotein(a) and dyslipidemia is not clear. This study was therefore undertaken to investigate the relationship between lipoprotein(a) and dyslipidemia in elderly patients over 60 years. From 2014 to 2020, a total of 2,580 adults aged 60 years or older (73.31±7.24 years, 1,954 males) were enrolled in the study. The patients had checked into a general hospital, and data were obtained for lipoprotein(a), LDL-C, TG, HDL-C, hs-CRP, HbA1c, sex, age, BMI, dyslipidemia diagnosis, and use of lipid-lowering agents. BMI and HbA1c showed no correlation with lipoprotein(a), but hs-CRP (r=0.138), LDL-C (r=0.097), HDL-C (r=‒0.089), TG (r=‒0.073), and age (r=0.072) were significantly correlated to lipoprotein(a). The partial correlation between lipoprotein(a) and LDL-C, which was adjusted for variables, was significant only in the male gender (r=0.158, P＜0.001). As the odds ratio of the 4th quartile of lipoprotein(a) (OR=1.376, 95% CI=1.038∼1.822) for dyslipidemia was found to be significant in this study when the level of LDL-C, the primary target, could not be reduced even by taking lipid-lowering drugs, we propose that lipoprotein(a) should also be included among the several factors considered as secondary targets. Our results indicate that studies on various lipid factors considering the sex, age, types and use of lipid-lowering agents, are warranted.
Abstract
The relationship between lipoprotein(a) and dyslipidemia is not clear. This study was therefore undertaken to investigate the relationship between lipoprotein(a) and dyslipidemia in elderly patients over 60 years. From 2014 to 2020, a total of 2,580 adults aged 60 years or older (73.31±7.24 years, 1,954 males) were enrolled in the study. The patients had checked into a general hospital, and data were obtained for lipoprotein(a), LDL-C, TG, HDL-C, hs-CRP, HbA1c, sex, age, BMI, dyslipidemia diagnosis, and use of lipid-lowering agents. BMI and HbA1c showed no correlation with lipoprotein(a), but hs-CRP (r=0.138), LDL-C (r=0.097), HDL-C (r=‒0.089), TG (r=‒0.073), and age (r=0.072) were significantly correlated to lipoprotein(a). The partial correlation between lipoprotein(a) and LDL-C, which was adjusted for variables, was significant only in the male gender (r=0.158, P＜0.001). As the odds ratio of the 4th quartile of lipoprotein(a) (OR=1.376, 95% CI=1.038∼1.822) for dyslipidemia was found to be significant in this study when the level of LDL-C, the primary target, could not be reduced even by taking lipid-lowering drugs, we propose that lipoprotein(a) should also be included among the several factors considered as secondary targets. Our results indicate that studies on various lipid factors considering the sex, age, types and use of lipid-lowering agents, are warranted.
참고문헌 (26)
- Ross R, "The pathogenesis of atherosclerosis—an update", N Engl J Med, 314, pp.488~500 (1986)[DOI]
- Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
- Papadopoulos N, "Serum lipoprotein patterns in patients with coronary atherosclerosis", Clin Chim Acta, 44, pp.153~157 (1973)[DOI]
- Nordestgaard B, "For the european athersclerosis society consensus panel : lipoprotein(a)as a cardiovascular risk factor; current status", Eur Heart J, 35, pp.1683~1693 (2014)[DOI]
- O’Donoghue ML, "Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk : insights from the FOURIER trial", Circulation, 139, pp.1483~1492 (2019)[DOI]
- Group H-TC, "Effects of extended-release niacin with laropiprant in high-risk patients", N Engl J Med, 371, pp.203~212 (2014)[DOI]
- Johannesen CDL, "Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients", J Am Coll Cardiol, 77, pp.1439~1450 (2021)[DOI]
- de Isla LP, "Comments on the 2019 ESC", EAS guidelines for the management of dyslipidemias, 2020, pp.73, 348~353
- Sunayama S, "Lack of increased coronary atherosclerotic risk due to elevated lipoprotein(a)in women≥ 55 years of age", Circulation, 94, pp.1263~1268 (1996)[DOI]
- Ravnskov U, "Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly : a systematic review", Br Med J, 6, pp.e010401~ (2016)[DOI]
- Ariyo AA, "Lp(a)lipoprotein, vascular disease, and mortality in the elderly", N Engl J Med, 349, pp.2108~2115 (2003)[DOI]
- KSoLA, "Korean guidelines for the management of dyslipidemia 4th ed", ~ (2018)
- Banach M, "Lipids, blood pressure and kidney update 2014", Pharmacol Res, 95, pp.111~125 (2015)[DOI]
- Romagnuolo R, "Lipoprotein(a)catabolism is regulated by proprotein convertase subtilisin", kexin type 9 through the low density lipoprotein receptor, 2015, pp.290, 11649~11662
- Rader DJ, "Variation in lipoprotein(a)concentrations among individuals with the same apolipoprotein(a)isoform is determined by the rate of lipoprotein(a)production", J Clin Invest, 91, pp.443~447 (1993)[DOI]
- Knight BL, "Catabolism of lipoprotein(a)in familial hypercholesterolaemic subjects", Atherosclerosis, 87, pp.227~237 (1991)[DOI]
- Zhang W, "High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein(a)multi-ethnic study of atherosclerosis", J Am Coll Cardiol, 78, pp.1083~1094 (2021)[DOI]
- Seman LJ, "Lipoprotein(a)-cholesterol and coronary heart disease in the framingham heart study", Clin Chem, 45, pp.1039~1046 (1999)[DOI]
- Zmuda JM, "Testosterone decreases lipoprotein(a)in men", Am J Cardiol, 77, pp.1244~1247 (1996)[DOI]
- Harman SM, "Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes", Am J Med, 124, pp.199~205 (2011)[DOI]
- Sahebkar A, "Lipid and blood pressure meta-analysis collaboration (LBPMC)group. the effects of tamoxifen on plasma lipoprotein (a) concentrations:systematic review and meta-analysis", Drugs, 77, pp.1187~1197 (2017)[DOI]
- Wang X, "Sex differences in lipid and lipoprotein metabolism : it's not just about sex hormones", J Clin Endocrinol Metab, 96, pp.885~893 (2011)[DOI]
- Li S, "Significance of lipoprotein(a)levels in familial hypercholesterolemia and coronary artery disease", Atherosclerosis, 260, pp.67~74 (2017)[DOI]
- Wang J, "Native, oxidized lipoprotein(a)and lipoprotein(a)immune complex in patients with active and inactive rheumatoid arthritis : plasma concentrations and relationship to inflammation", Clin Chim Acta, 390, pp.67~71 (2008)[DOI]
- Berg K, "A new serum type system in man—the Lp system", Acta Pathol Microbiol Scand, 59, pp.369~382 (1963)[DOI]
- Opoku S, "Prevalence and risk factors for dyslipidemia among adults in rural and urban china : findings from the china national stroke screening and prevention project(CNSSPP)", BMC public health, 19, pp.1~15 (2019)[DOI]